NASDAQ:BBNX
Beta Bionics, Inc.
Beta Bionics, Inc.'s revenue grew 53.9% in fiscal 2025 to $100.3M while operating margin fell to −71.5%. Free cash flow was −$56.2M, −56.1% of revenue, and the diluted share count rose 536.7%.Summary generated from Beta Bionics, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$100.3M
Revenue growth+53.9%
Revenue, 5-yr CAGRn/a
Gross margin55.4%
Operating margin−71.5%
Net margin−73.0%
ROICn/a
Return on equity−346.5%
Debt / equityn/a
Free cash flow−$56.2M
FCF margin−56.1%
Share count change+536.7%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 12 | 65 | 100 |
| Operating income | −36 | −45 | −72 |
| Net income | −44 | −55 | −73 |
| Free cash flow | −33 | −52 | −56 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Sep 23, 2026 - 8-KOther events
Sep 17, 2026 - 8-KRegulation FD disclosure
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 8-KResults of a shareholder vote
May 22, 2026 - 8-KRegulation FD disclosure
May 21, 2026